Phase III Trial Of Nexavar In Patients With Advanced Melanoma Does Not Meet Primary Endpoint

Tue, 05 Dec 2006 02:00 PM EST

... Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase III trial administering Nexavar(R) (sorafenib) or placebo tablets in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with advanced melanoma did not meet its primary endpoint of improving progression-free survival (PFS). [click link for full article] ...